Accenture, Abivax and 3 Stocks to Watch Heading Into Monday
Stocks in focus: Abivax, Marygold and Neuphoria report losses; Accenture partners with Anthropic, while Lobo Technologies posts H1 growth.
Stocks · News reference
Neuphoria Therapeutics Q4 EPS $(0.95) Misses $(0.56) Estimate, Sales $1.174M.
Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.56) by 69.64 percent. This is a 76.13 percent increase over losses of $(3.98) per
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAX
Monteverde & Associates PC is investigating four major M&A transactions on behalf of shareholders: Northrim Bancorp's merger with PBCO Financial Corporation, Neuphoria Therapeutics' merger with Scancell Holdings plc, Safety Insurance Group's sale to a Mapfre affiliate, and RE/MAX Holdings' sale to The Real Brokerage Inc. The firm encourages shareholders to contact them regarding potential concerns with these deals.
8-K filing — Neuphoria Therapeutics Inc. (NEUP)
Filed: 2026-07-24 AccNo: 0001213900-26-081052 Size: 18 MB Item 1.01: Entry into a Material Definitive Agreement Item 5.01: Changes in Control of Registrant Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits